STING1
STING1
Overview
STING1 (Stimulator of Interferon Genes 1), encoded by the gene TMEM173 (also catalogued as Wikidata Q18055374), is a transmembrane adaptor protein that serves as a central hub in the innate immune sensing pathway. Located on the endoplasmic reticulum membrane, STING1 functions downstream of cyclic GMP-AMP synthase (cGAS), which detects cytosolic double-stranded DNA from damaged, infected, or malignant cells. Upon activation by cyclic dinucleotides (CDNs) — including the second messenger cGAMP produced by cGAS — STING1 undergoes conformational changes that recruit and activate TBK1 and IRF3, ultimately driving transcription of type I interferons and other pro-inflammatory cytokines. This signaling cascade, collectively known as the cGAS–STING pathway, bridges the detection of nucleic acid danger signals to a robust adaptive immune response, making the p53/cGAS/STING axis a critical checkpoint in tumor surveillance and antiviral defense.
Because STING1 occupies a nodal position in innate immunity, it has attracted intense interest as a therapeutic target in oncology and inflammatory disease. Pharmacological agonists of STING1 can reprogram the immunosuppressive tumor microenvironment by recruiting and activating dendritic cells and other immune effectors, thereby potentiating cancer immunotherapy. Conversely, in conditions of chronic sterile inflammation — such as pulmonary fibrosis — pathological STING1 activity in macrophages drives tissue damage, making its targeted silencing equally therapeutically relevant.
Recent Publications Focus
Below is a summary of the newest research publications targeting STING1 (sorted by publication date).
Recent studies have explored STING as a therapeutic target across pulmonary fibrosis and cancer immunotherapy, employing diverse modulation strategies including protein degradation, gene editing, agonism, and combination approaches. In idiopathic pulmonary fibrosis, STING has emerged as a driver of senescence-associated inflammatory signaling. An inhalable polymeric PROTAC nanococktail demonstrated that concurrent degradation of STING and BRD4 in fibrotic lungs suppressed epithelial senescence-linked inflammation and fibroblast activation, achieving superior therapeutic efficacy compared to single-agent treatments in bleomycin-induced pulmonary fibrosis models [42341263]. Complementarily, a macrophage-targeted lipid nanoparticle platform delivering CRISPR-Cas9 mRNA for in vivo Sting1 gene editing showed that selective STING disruption in alveolar macrophages reduced pro-fibrotic cytokine secretion and significantly attenuated collagen deposition and fibrosis progression [41795185].
In cancer immunotherapy, STING activation has been leveraged to enhance innate immune responses and overcome immune evasion across multiple solid tumors. A cyclic dinucleotide-loaded peptide hydrogel-liposome composite system enabled prolonged intratumoral STING agonist availability in oral squamous cell carcinoma, achieving survival equivalent to six repeated injections with a single dose [41702512]. An X-ray-responsive nanoplatform demonstrated that radiotherapy-triggered Mn2+ release amplifies cGAS-STING signaling to enhance interferon-β secretion and dendritic cell maturation, synergistically improving radiosensitivity and systemic immune activation [42023514]. A metal-organic framework nanodrug combining CD47 blockade with STING agonist diABZI delivery showed superior melanoma control and survival prolongation through integrated "don't eat me" signal suppression and STING-mediated innate activation [41723989]. pH-responsive co-delivery of STING agonists and Indoleamine 2,3-dioxygenase 1 inhibitors demonstrated that combined STING activation and IDO1 blockade within type I conventional dendritic cells synergistically enhances antigen cross-presentation and cytotoxic T lymphocyte priming, with host STING expression proving essential for therapeutic efficacy [41702511].
STING's regulatory landscape and emerging agonist development have also advanced substantially. In renal cell carcinoma, STING promoter hypomethylation correlated with elevated STING mRNA expression, advanced clinicopathological features, poor overall survival, and increased CD4 and CD8 T-cell infiltration, positioning STING promoter methylation as a potential biomarker for predicting immunotherapy responses [41942521]. Benzimidazole-derived non-cyclic dinucleotide STING agonists have emerged as promising alternatives to classical cyclic dinucleotide agonists, offering improved cell permeability, pharmacokinetics, and oral bioavailability with enhanced capacity to trigger interferon production and immune responses [41785706]. A biodegradable Mn(III)-based sonozyme system harnessed STING activation alongside sonodynamic therapy and nanozyme-mediated reactive oxygen species generation and hypoxia alleviation, achieving enhanced efficacy against local and metastatic tumors [41512497]. As a transmembrane protein within the broader tumor immune microenvironment, STING exemplifies dual functional potential in promoting antitumor immunity through immune activation while remaining subject to context-dependent regulatory mechanisms [41864016].